Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

IDRA / Idera Pharmaceuticals, Inc. 425 (Prospectus)

2018-02-23 sec.gov
  Filed by Idera Pharmaceuticals, Inc. pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: BioCryst Pharmaceuticals, Inc. Commission File No. of Subject Company: 000-23186   RBC Capital Markets 2018 Global Healthcare Conference February 21, 2018, 3:00 PM EST   Brian Abrahams:  I’m Brian Abrahams, one of the senior biotechnology analysts here at RBC Capital Markets. (71-0)

IDRA / Idera Pharmaceuticals, Inc. 425 (Prospectus)

2018-02-23 sec.gov
  Filed by Idera Pharmaceuticals, Inc. pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: BioCryst Pharmaceuticals, Inc. Commission File No. of Subject Company: 000-23186   RBC Capital Markets 2018 Global Healthcare Conference February 21, 2018, 3:00 PM EST   Brian Abrahams:  I’m Brian Abrahams, one of the senior biotechnology analysts here at RBC Capital Markets. (71-0)

IDRA / Idera Pharmaceuticals, Inc. 425 (Prospectus)

2018-02-22 sec.gov
  Filed by Idera Pharmaceuticals, Inc. pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: BioCryst Pharmaceuticals, Inc.. Commission File No. of Subject Company: 000-23186     Combining Capabilities to Serve More Patients with Rare Diseases   This press release contains forward-looking statements within the meaning of the federal securities law. (71-0)

IDRA / Idera Pharmaceuticals, Inc. 425 (Prospectus)

2018-02-22 sec.gov
  Filed by Idera Pharmaceuticals, Inc. pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: BioCryst Pharmaceuticals, Inc.. Commission File No. of Subject Company: 000-23186     Combining Capabilities to Serve More Patients with Rare Diseases   This press release contains forward-looking statements within the meaning of the federal securities law. (71-0)

BioXcel Therapeutics Seeks $69 Million U.S. IPO

2018-02-16 seekingalpha
The firm is using the advanced data and AI technologies of its parent company to improve its drug development efforts. (381-3)

BiolineRx Has Huge Upside In 2018

2018-01-29 seekingalpha
In two January ASCO presentations, BL-8040 showed robust infiltration of anti-tumor T-cells into liver metastases in pancreatic cancer and primes the tumor micro-environment to enhance the effectiveness of immunotherapy agents. (418-14)

BioCryst (BCRX) & Idera (IDRA) Announce Merger, Shares Fall

2018-01-23 zacks
BioCryst Pharmaceuticals, Inc. (BCRX - Free Report) and Idera Pharmaceuticals, Inc. (IDRA - Free Report) announced that they have entered into a definitive merger agreement. The merged entity will focus on development and commercialization of drugs to treat rare diseases. (128-5)

IDRA / Idera Pharmaceuticals, Inc. 425 (Prospectus)

2018-01-23 sec.gov
  Filed by Idera Pharmaceuticals, Inc. pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Idera Pharmaceuticals, Inc. Commission File No. of Subject Company: 001-31918     Client Id: 77 THOMSON REUTERS STREETEVENTS PRELIMINARY TRANSCRIPT BCRX - BioCryst Pharmaceuticals Inc and Idera Pharmaceuticals Inc to Announce Merger - M&A Call EVENT DATE/TIME: JANUARY 22, 2018 / 3:00PM GMT THOMSON REUTERS

IDRA / Idera Pharmaceuticals, Inc. 425 (Prospectus)

2018-01-22 sec.gov
  Filed by Idera Pharmaceuticals, Inc. pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Idera Pharmaceuticals, Inc. Commission File No. of Subject Company: 001-31918     Frequently Asked Questions   FAQs — Internal Use Only - Not for General Distribution   1.              What’s happening?  Idera and BioCryst have entered into a merger agreement that will result in combining the assets and st

IDRA / Idera Pharmaceuticals, Inc. 425 (Prospectus)

2018-01-22 sec.gov
  Filed by Idera Pharmaceuticals, Inc. pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Idera Pharmaceuticals, Inc. Commission File No. of Subject Company: 001-31918     Frequently Asked Questions   For External Communications   1)             Transaction Related   a.              Why now?  The two parties have engaged in discussion for some time and both recognize that combining creates the

IDRA / Idera Pharmaceuticals, Inc. 425 (Prospectus)

2018-01-22 sec.gov
  Filed by Idera Pharmaceuticals, Inc. pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Idera Pharmaceuticals, Inc. Commission File No. of Subject Company: 001-31918   IDRA/BCRX Merger Announcement Investor Conference call January 22, 2018, 10:00 AM ET   Speaker Dial in: United States:  844-889-6870 International:  574-990-9856 Conference ID: 4186878   Operator:   Good morning and welcome eve

IDRA / Idera Pharmaceuticals, Inc. 425 (Prospectus)

2018-01-22 sec.gov
  Combining Capabilities to Serve More Patients with Rare Diseases + Filed by Idera Pharmaceuticals, Inc. pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Idera Pharmaceuticals, Inc. Commission File No. of Subject Company: 001-31918   Forward Looking Statements + 2 This press release contains forward-looking statements within the meaning of the federal securities law.

IDRA / Idera Pharmaceuticals, Inc. 425 (Prospectus)

2018-01-22 sec.gov
  Filed by Idera Pharmaceuticals, Inc. pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: Idera Pharmaceuticals, Inc. Commission File No. of Subject Company: 001-31918     BioCryst Pharmaceuticals and Idera Pharmaceuticals Announce Merger to Combine Capabilities to Serve More Patients with Rare Diseases   - Combination creates a well-funded company with a diversified late-stage clinical pipelin

BRIEF-Biocryst Pharma And Idera Pharma Sign Merger Agreement To Form New Company

2018-01-22 reuters
* BIOCRYST PHARMACEUTICALS AND IDERA PHARMACEUTICALS ANNOUNCE MERGER TO COMBINE CAPABILITIES TO SERVE MORE PATIENTS WITH RARE DISEASES (72-0)


IDRA : Idera Pharmaceuticals Stock Analysis and Research Report

Idera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel oligonucleotide therapeutics for oncology and rare diseases. Idera Pharmaceuticals use two distinct proprietary drug discovery technology platforms to design and develop drug candidates: its Toll-like receptor, or TLR, targeting technology and its third-generation antisense, or 3GA, technology. Idera Pharmaceuticals developed these platforms based on its scientific expertise and pioneering work with synthetic oligonucleotides as therapeutic agents. Using its TLR targeting technology, Idera Pharmaceuticals design synthetic oligonucleotide-based drug candidates to modulate the activity of specific TLRs. In addition, using its 3GA technology, Idera Pharmaceuticals is developing drug candidates to turn off the messenger RNA, or mRNA, associated with disease causing genes. Idera Pharmaceuticals believe its 3GA technology may potentially reduce the immunoto...

Click for full article
CUSIP: 45168K306